الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 100 |  |  |
| | | from | 100 | | |
Abstract
Cervical cancer is the fourth most common illness diagnosed in women globally, with over 570,000 cases recorded in 2018. This accounts for 6.6% of all female malignancies. More than % of the 311,000 women who died from cervical cancer in 2018 lived in low and middle-income countries.
Cervical cancer is the ninth most common malignancy in women between the ages of 15 and 44 in Egypt, with a per year occurrence of 2.3 per 100,000 individuals.
Furthermore, cervical cancer is the 12th leading cause of cancer death amongst Egyptian women aged 15-44.
Multiple factors have been demonstrated to enhance the risk of acquiring cervical cancer. Despite this, the idea that HPV infections cause a high percentage of cervical cancer cases is commonly held. Cervical cancer is primarily caused by infection with high-risk human papillomavirus (HPV), however HPV infection is also associated with the development of other types of cancer.
For many years, the Papanicolaou (Pap) test has been the gold standard for cytology tests in the fight against cervical cancer.
The extent to which Egypt’s government would pay for a test to detect cervical cancer was unclear. The lack of awareness about cervical cancer among both patients and doctors contributes significantly to the poor screening rates. Screening with the Pap test and vaccination against hpv infection have the potential to greatly reduce the global incidence of cervical cancer.
Healthcare providers are vital in raising public knowledge and bolstering the public’s attitude and practises, supposing the public has an adequate and up-to-date degree of information and a positive outlook.